Search results
BioNTech SE (NASDAQ:BNTX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Simply Wall St. via Yahoo Finance· 22 hours agoInvestors in BioNTech SE (NASDAQ:BNTX) had a good week, as its shares rose 2.3% to close at US$90.88...
BioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoBioNTech SE (NASDAQ:BNTX) Q1 2024 Earnings Call Transcript May 6, 2024 BioNTech SE isn’t one of the...
BioNTech Target of Unusually Large Options Trading (NASDAQ:BNTX)
ETF DAILY NEWS· 1 day agoBioNTech SE (NASDAQ:BNTX – Get Free Report) was the recipient of some unusual options trading on Monday. BMO Capital Markets cut their price objective on BioNTech ...
Earnings call: BioNTech targets oncology growth, plans new COVID vaccine By Investing.com
Investing.com· 2 days agoBioNTech SE (NASDAQ:BNTX), a biotechnology company, reported its first-quarter financial results for...
What's Going With BioNTech Stock On Monday?
Benzinga· 3 days agoMonday, BioNTech SE BNTX reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss...
BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come
Investor's Business Daily· 2 days agoBioNTech stock seesawed before closing in the green on Monday following a disappointing...
AstraZeneca pulls its COVID-19 vaccine from the European market
WSB-TV 2 Atlanta· 8 hours agoLONDON — (AP) — The pharma giant AstraZeneca has requested that the European authorization for its...
BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales
Barrons.com· 3 days agoFEATURE U.S.-listed shares of BioNTech were falling Monday after the German company that partnered...
BioNTech says 90% of 2024 revenues will accrue at end of year
Reuters· 3 days ago, opens new tab was widely used during the pandemic, said on Monday that almost all of its expected...
Cracking The Code: Understanding Analyst Reviews For BioNTech - BioNTech (NASDAQ:BNTX)
Benzinga· 2 days agoLoading... Loading... Throughout the last three months, 12 analysts have evaluated BioNTech BNTX , offering a diverse set of opinions from bullish to bearish. The table below ...